Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences Q3 revenue up 5.6% to $402.1 million; 2025 revenue guidance revised

Mixed Impact 4 of 5 earnings Written later

Integra reported third quarter 2025 revenue of $402.1 million, up 5.6% from a year earlier, and a GAAP net loss of $(5.4) million, or $(0.07) per diluted share, compared with a loss of $(0.14) per share a year earlier. Adjusted EPS rose to $0.54 from $0.41, but the company said two supply interruptions weighed on revenue and it revised its 2025 revenue guidance, with fourth-quarter reported revenue expected to decline year over year, which matters to shareholders weighing the outlook.

Key points

  • Q3 revenue of $402.1 million rose 5.6% reported and 5.0% organic; Codman Specialty Surgical was $292.6 million and Tissue Technologies was $109.5 million
  • GAAP net loss narrowed to $(5.4) million, or $(0.07) per diluted share, from $(10.7) million, or $(0.14), a year earlier; adjusted EPS was $0.54 versus $0.41
  • Full-year 2025 revenue guidance updated to $1.620 billion to $1.640 billion; adjusted EPS guidance of $2.19 to $2.24 for the full year
  • Fourth-quarter 2025 reported revenue expected at $420 million to $440 million, representing reported growth of (5.1%) to (0.6%)

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECOct 30, 2025, 6:15 AM ET
Accession number0000917520-25-000094

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.